Drug Search Results
More Filters [+]

Caltrate d

Alternative Names: caltrate D, calcichew D3, calcichew D3 forte, calcichew-D3, calcichew-D3 forte, calcium/colecalciferol, calcium-colecalciferol
Latest Update: 2024-05-10
Latest Update Note: PubMed Publication

Product Description

Treatment with Rocaltrol plus Caltrate D or Caltrate D for 12 months in elderly Chinese postmenopausal women effectively increased BMD at the lumbar spine. Rocaltrol plus Caltrate D was more effective at the lumbar spine than Caltrate D alone. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19262561/)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Chile | Colombia | Czech | Denmark | Finland | Hungary | Ireland | Slovakia | Sweden | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Caltrate d

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Vitamin D Deficiency|Osteoporosis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2200066020

N/A

Not yet recruiting

Osteoporosis

2023-10-25

ZZ13-YQ-039

N/A

Unknown status

Osteoporosis

2022-12-01

ChiCTR-IPR-15007081

N/A

Completed

Breast Cancer|Bone Cancer

2016-03-06

2014-005619-18

P4

Completed

Osteoporosis|Vitamin D Deficiency

2015-08-21

Recent News Events